In this study, we proposed a potential method for the preparation of a magnesium-based medical device for local drug delivery and controlled corrosion. A magnesium surface was modified with 3-aminopropyltrimethoxy silane, and the resulting surface was then coated with drug-loaded nanoparticles made of poly (lactic-co-glycolic acid) via electrophoretic deposition. The drug-loaded nanoparticles (i.e., Tr_NP) exhibited a size of 250 ± 67 nm and a negative zeta potential of −20.9 ± 2.75 mV. The drug was released from the nanoparticles in a sustained manner for 21 days, and this did not change after their coating on the silane-modified magnesium. The silane-modified surface suppressed magnesium corrosion. When immersed in phosphate buffered saline at pH 7.4, the average rate of hydrogen gas generation was 0.41–0.45 ml/cm2/day, compared to 0.58–0.6 ml/cm2/day from a bare magnesium surface. This corrosion profile was not significantly changed after nanoparticle coating under the conditions employed in this work. The in vitro cell test revealed that the drug released from the coating was effective during the whole release period of 21 days, and both the silane-modified surface and carrier nanoparticles herein were not cytotoxic.
ZhangSZhangXZhaoC. Research on an Mg–Zn alloy as a degradable biomaterial. Acta Biomater2010; 6: 626–640.
2.
ParkMLeeJEParkCG. Polycaprolactone coating with varying thicknesses for controlled corrosion of magnesium. Journal of Coatings Technology and Research2013; 10: 695–706.
3.
WangHShiZ. In vitro biodegradation behavior of magnesium and magnesium alloy. J Biomed Mater Res B Appl Biomater2011; 98: 203–209.
4.
StaigerMPPietakAMHuadmaiJ. Magnesium and its alloys as orthopedic biomaterials: a review. Biomaterials2006; 27: 1728–1734.
SchwartzRSChronosNAVirmaniR. Preclinical restenosis models and drug-eluting stents: still important, still much to learn. J Am Coll Cardiol2004; 44: 1373–1385.
7.
TanabeKRegarELeeCH. Local drug delivery using coated stents: new developments and future perspectives. Curr Pharmaceut Des2004; 10: 357–367.
8.
KandzioraFBailHSchmidmaierG. Bone morphogenetic protein-2 application by a poly (D, L-lactide)-coated interbody cage: in vivo results of a new carrier for growth factors. J Neurosurg Spine2002; 97: 40–48.
9.
LeachJKMooneyDJ. Bone engineering by controlled delivery of osteoinductive molecules and cells. Exp Opin Biologic Ther2004; 4: 1015–1027.
10.
DarouicheROSmithJAJrHannaH. Efficacy of antimicrobial-impregnated bladder catheters in reducing catheter-associated bacteriuria: a prospective, randomized, multicenter clinical trial. Urology1999; 54: 976–981.
11.
RichardsCLHoffmanKCBernhardJM. Development and characterization of an infection inhibiting urinary catheter. ASAIO J2003; 49: 449–453.
12.
WuPGraingerDW. Drug/device combinations for local drug therapies and infection prophylaxis. Biomaterials2006; 27: 2450–2467.
13.
ChenYSongYZhangS. Interaction between a high purity magnesium surface and PCL and PLA coatings during dynamic degradation. Biomed Mater2011; 6: 025005–025005.
14.
MillerABergJ. Effect of silane coupling agent adsorbate structure on adhesion performance with a polymeric matrix. Compos A Appl Sci Manuf2003; 34: 327–332.
15.
MittalKL. Silanes and other coupling agents, vol. 4. London: CRC Press, 2007.
16.
ZucchiFGrassiVFrignaniA. Influence of a silane treatment on the corrosion resistance of a WE43 magnesium alloy. Surf Coat Technol2006; 200: 4136–4143.
17.
ZucchiFFrignaniAGrassiV. Organo-silane coatings for AZ31 magnesium alloy corrosion protection. Mater Chem Phys2008; 110: 263–268.
18.
KurthDGBeinT. Surface reactions on thin layers of silane coupling agents. Langmuir1993; 9: 2965–2973.
19.
Jawahar N, Eagappanath T, Venkatesh N, et al. Preparation and characterisation of PLGA-nanoparticles containing an anti-hypertensive agent. Int J PharmTech Res 2009; 1.
20.
NamSHNamHYJooJR. Curcumin-loaded PLGA nanoparticles coating onto metal stent by electrophoretic deposition techniques. Bull-Korean Chem Soc2007; 28: 397–397.
21.
Wang Y and Burgess D. Drug ± device combination products. Drug-Device Comb Prod Delivery Technol Appl 2009: 1.
22.
SuzawaHKikuchiSAraiN. The mechanism involved in the inhibitory action of tranilast on collagen biosynthesis of keloid fibroblasts. Jpn J Pharmacol1992; 60: 91–96.
23.
XinYHuTChuPK. Influence of test solutions on in vitro studies of biomedical magnesium alloys. J Electrochem Soc2010; 157: C238–C243.
24.
MainardesRMEvangelistaRC. PLGA nanoparticles containing praziquantel: effect of formulation variables on size distribution. Int J Pharmaceut2005; 290: 137–144.
25.
ZhuRZhangJChangC. Effect of silane and zirconia on the thermal property of cathodic electrophoretic coating on AZ31 magnesium alloy. J Magnesium Alloy2013; 1: 235–241.
26.
LeeJ-YHanGKimY-C. Effects of impurities on the biodegradation behavior of pure magnesium. Metals Mater Int2009; 15: 955–961.
27.
Use of International Standard ISO-110993, “Biological Evaluation of Medical Devices Part 1: Evaluation and Testing”. Department of Health and Human Services, Food and Drug Administration, Center for Devices and Radiological Health, Office of Device Evaluation, 2013.
28.
KawabataYYamamotoKDebariK. Novel crystalline solid dispersion of tranilast with high photostability and improved oral bioavailability. Eur J Pharmaceut Sci2010; 39: 256–262.
29.
XinFJianCJianmingR. Effects of surface modification on the properties of poly (lactide-co-glycolide) composite materials. Polym Plast Technol Eng2009; 48: 658–664.
30.
Darakhshan S and Pour AB. Tranilast: a review of its therapeutic applications. Pharmacol Res 2015; 91: 15–28.
31.
WitteF. The history of biodegradable magnesium implants: a review. Acta Biomater2010; 6: 1680–1692.
32.
WitteFKaeseVHaferkampH. In vivo corrosion of four magnesium alloys and the associated bone response. Biomaterials2005; 26: 3557–3563.
33.
SongJVan OoijWJ. Bonding and corrosion protection mechanisms of γ-APS and BTSE silane films on aluminum substrates. J Adhes Sci Technol2003; 17: 2191–221.
34.
FourcheG. An overview of the basic aspects of polymer adhesion. Part II: application to surface treatments. Polym Eng Sci1995; 35: 968–975.
35.
Zhu D. Corrosion protection of metals by silane surface treatment. University of Cincinnati, 2005.
36.
PanyamJLabhasetwarV. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Delivery Rev2003; 55: 329–347.
37.
LungCYKMatinlinnaJP. Aspects of silane coupling agents and surface conditioning in dentistry: an overview. Dental Mater2012; 28: 467–577.
38.
MatinlinnaJPLassilaLVÖzcanM. An introduction to silanes and their clinical applications in dentistry. Int J Prosthodont2004; 17: 155–164.
39.
ZhangJWuC. Corrosion protection behavior of AZ31 magnesium alloy with cathodic electrophoretic coating pretreated by silane. Progr Organic Coat2009; 66: 387–392.
40.
MontemorMFerreiraM. Electrochemical study of modified bis-[triethoxysilylpropyl] tetrasulfide silane films applied on the AZ31 Mg alloy. Electrochimica Acta2007; 52: 7486–7495.
